Pramod Krishnappa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pramod Krishnappa has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Ignacio Moncada
Department of Urology and Robotic Surgery La Zarzuela University Hospital Madrid Spain
12 shared publicationsPrasanna Matippa
Department of Urology and Reproductive Medicine, NU Hospitals, Orchidz Health , Bangalore 560010
6 shared publicationsJuan Ignacio Martinez-Salamanca
Lyx Institute of Urology, Francisco de Vitoria University, Madrid 28006, Spain
5 shared publicationsRupin Shah
Lilavati Hospital and Research Center Department of Urology Mumbai 400050
5 shared publicationsVenkatesh Krishnamoorthy
Department of Urology, NU Hospitals, Bengaluru, Karnataka, India
5 shared publicationsEnrique Lledo-Garcia
Department of Urology, Gregorio Maranon University General Hospital, Complutense University, Madrid, Spain
4 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Elsevier in Pharmacological Reviews
Pharmacological Therapies for Erectile Dysfunction: A Historical and Contemporary Perspective
- 16 November 2026
- Published by Elsevier in Pharmacological Reviews
Open AccessPharmacological Therapies for Erectile Dysfunction: A Historical and Contemporary Perspective
- Open Access
- 5 January 2026
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (1)
Sexual dysfunctions in male patients with infertility: recommendations from the Fifth International Consultation for Sexual Medicine (ICSM 2024)
Introduction: The issue of sexual dysfunction in infertile couples is often neglected and underreported. As sexual dysfunction can both contribute to and result from infertility, clinicians should be equipped to identify and address these issues as part of comprehensive fertility care. Objectives: To develop evidence- and consensus-based recommendations for the clinical management of male sexual dysfunction (MSD) in the context of infertility. Methods: Initial recommendations were formulated based on expert opinion and exploratory analysis of various types of MSD associated with infertility. A focused literature review was conducted for each topic, followed by iterative rounds of expert discussion to refine recommendations. Final consensus was achieved at the 5th International Consultation on Sexual Medicine meeting, and recommendations were rated using GRADE criteria. Results: MSD and infertility often coexist, necessitating a detailed sexual history and physical examination during the initial infertility evaluation. Erectile dysfunction may be effectively managed with counseling, phosphodiesterase-5 inhibitors, or intracavernosal injections (eg, alprostadil, papaverine, phentolamine), which do not impair fertility outcomes. For low libido or unconsummated marriages, a multidisciplinary approach tailored to the couple’s priorities—sexual function or fertility—is recommended. Ejaculatory disorders may be treated with counseling, penile vibratory stimulation, electro-ejaculation, medications, or assisted reproduction, depending upon the underlying cause. Selective serotonin reuptake inhibitors, used for premature ejaculation, may adversely affect sperm parameters and should be prescribed cautiously. Men with hypogonadism seeking fertility should avoid exogenous testosterone; alternatives such as selective estrogen receptor modulators, aromatase inhibitors, or gonadotropins may be considered. Lifestyle optimization, management of comorbidities, and use of fertility-safe lubricants can improve sexual and reproductive outcomes for couples trying to conceive. Conclusion: MSD and infertility are often interrelated. Incorporating routine sexual health assessments into fertility evaluations enables clinicians to diagnose and treat MSD effectively, thereby improving both sexual function and reproductive success.
- 5 January 2026
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (1)
Open AccessSexual dysfunctions in male patients with infertility: recommendations from the Fifth International Consultation for Sexual Medicine (ICSM 2024)
Introduction: The issue of sexual dysfunction in infertile couples is often neglected and underreported. As sexual dysfunction can both contribute to and result from infertility, clinicians should be equipped to identify and address these issues as part of comprehensive fertility care. Objectives: To develop evidence- and consensus-based recommendations for the clinical management of male sexual dysfunction (MSD) in the context of infertility. Methods: Initial recommendations were formulated based on expert opinion and exploratory analysis of various types of MSD associated with infertility. A focused literature review was conducted for each topic, followed by iterative rounds of expert discussion to refine recommendations. Final consensus was achieved at the 5th International Consultation on Sexual Medicine meeting, and recommendations were rated using GRADE criteria. Results: MSD and infertility often coexist, necessitating a detailed sexual history and physical examination during the initial infertility evaluation. Erectile dysfunction may be effectively managed with counseling, phosphodiesterase-5 inhibitors, or intracavernosal injections (eg, alprostadil, papaverine, phentolamine), which do not impair fertility outcomes. For low libido or unconsummated marriages, a multidisciplinary approach tailored to the couple’s priorities—sexual function or fertility—is recommended. Ejaculatory disorders may be treated with counseling, penile vibratory stimulation, electro-ejaculation, medications, or assisted reproduction, depending upon the underlying cause. Selective serotonin reuptake inhibitors, used for premature ejaculation, may adversely affect sperm parameters and should be prescribed cautiously. Men with hypogonadism seeking fertility should avoid exogenous testosterone; alternatives such as selective estrogen receptor modulators, aromatase inhibitors, or gonadotropins may be considered. Lifestyle optimization, management of comorbidities, and use of fertility-safe lubricants can improve sexual and reproductive outcomes for couples trying to conceive. Conclusion: MSD and infertility are often interrelated. Incorporating routine sexual health assessments into fertility evaluations enables clinicians to diagnose and treat MSD effectively, thereby improving both sexual function and reproductive success.
- 21 November 2025
- Published by Wiley in International Journal of Urology
- Vol. 33 (1)
A Comparative Study of Simultaneous and Delayed Penile Prosthesis During Robot‐Assisted Radical Prostatectomy
Objectives: To compare sexual rehabilitation outcomes in prostate cancer patients with preexisting erectile dysfunction (ED) undergoing simultaneous vs. delayed inflatable penile prosthesis (PP) placement during robot‐assisted radical prostatectomy (RARP). Methods: Fifty‐six patients with refractory ED and prostate cancer (2011–2023) were included. Simultaneous RARP and inflatable PP placement was done in 29 patients. Twenty‐seven patients underwent RARP followed by delayed inflatable PP placement after a mean of 3.28 years. The same surgeon performed both RARP and inflatable PP implantation. Modified Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), EORTC Sexual Health Scores, and penile length changes were evaluated at 1 year. Results: Mean age of the simultaneous and delayed PP group was 64.41 and 62.66 years, respectively. The simultaneous group had a higher percentage of severe ED (55.2% vs. 25.9%). At 1 year, simultaneous group patients had significantly better mean Modified EDITS (79.1 vs. 61.1, p < 0.001) and better EORTC Sexual Health scores (62.5 vs. 47.1, p < 0.001). Penile length loss was significantly less in the simultaneous group compared to the delayed group (0.32 ± 0.29 cm vs. 1.43 ± 0.36 cm, p < 0.001). Positive surgical margin (13.7% vs. 18.5%) and biochemical recurrence at 2 years (10.3% vs. 14.8%) showed no significant difference between the simultaneous and delayed PP groups, respectively. No major complications were observed in either group. Conclusion: Simultaneous inflatable PP with RARP is safe and provides early sexual rehabilitation, improves patients' quality of life and maintains penile length without compromising surgical and oncological outcomes.
- 21 November 2025
- Published by Wiley in International Journal of Urology
- Vol. 33 (1)
A Comparative Study of Simultaneous and Delayed Penile Prosthesis During Robot‐Assisted Radical Prostatectomy
Objectives: To compare sexual rehabilitation outcomes in prostate cancer patients with preexisting erectile dysfunction (ED) undergoing simultaneous vs. delayed inflatable penile prosthesis (PP) placement during robot‐assisted radical prostatectomy (RARP). Methods: Fifty‐six patients with refractory ED and prostate cancer (2011–2023) were included. Simultaneous RARP and inflatable PP placement was done in 29 patients. Twenty‐seven patients underwent RARP followed by delayed inflatable PP placement after a mean of 3.28 years. The same surgeon performed both RARP and inflatable PP implantation. Modified Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), EORTC Sexual Health Scores, and penile length changes were evaluated at 1 year. Results: Mean age of the simultaneous and delayed PP group was 64.41 and 62.66 years, respectively. The simultaneous group had a higher percentage of severe ED (55.2% vs. 25.9%). At 1 year, simultaneous group patients had significantly better mean Modified EDITS (79.1 vs. 61.1, p < 0.001) and better EORTC Sexual Health scores (62.5 vs. 47.1, p < 0.001). Penile length loss was significantly less in the simultaneous group compared to the delayed group (0.32 ± 0.29 cm vs. 1.43 ± 0.36 cm, p < 0.001). Positive surgical margin (13.7% vs. 18.5%) and biochemical recurrence at 2 years (10.3% vs. 14.8%) showed no significant difference between the simultaneous and delayed PP groups, respectively. No major complications were observed in either group. Conclusion: Simultaneous inflatable PP with RARP is safe and provides early sexual rehabilitation, improves patients' quality of life and maintains penile length without compromising surgical and oncological outcomes.
- 12 September 2025
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (1)
Virtual reality in the management of male sexual dysfunction: an updated narrative review of the literature
Introduction: Virtual reality (VR) has emerged as a promising technology in medicine, offering innovative approaches for diagnostics, treatment, and patient education. However, its role in male sexual dysfunction (MSD) management remains underexplored, particularly among urologists. Objectives: To review the current evidence on the use of VR in the diagnosis and treatment of MSDs, assessing its feasibility, efficacy, and potential integration into clinical practice. Methods: A comprehensive bibliographic search for a narrative review was conducted in October 2024 using Google Scholar, PubMed, Scopus, and Web of Science to identify literature on VR applications in MSD management. The PICO framework of article selection was employed to include prospective and retrospective studies evaluating VR-based diagnostic and therapeutic interventions for MSD. Studies involving nonmale participants, nonsexual applications of VR, and technologies not classified as immersive VR (eg, televisions and laptops) were excluded. Results: In erectile dysfunction, VR-based audiovisual sexual stimulation (VR-AVSS) has demonstrated potential for assessing erectile function, providing an objective measure of arousal through RigiScan-based monitoring. Additionally, VR has been studied in psychosexual therapy, showing promise in managing performance anxiety and related psychological factors contributing to MSDs. In premature ejaculation, VR-based interventions may complement existing psychosexual and pharmacological treatments by facilitating behavioral training in immersive environments. While no clinical studies have directly examined VR applications in Peyronie’s disease, theoretical models suggest its utility in patient education and 3-dimensional curvature simulation, aiding treatment planning and adherence. Emerging applications of VR in forensic settings include the assessment of sexual preferences, aversion disorders, and deviant sexual behaviors, utilizing physiological and eye-tracking metrics to enhance diagnostic accuracy. Conclusion: While current research has predominantly focused on psychological interventions, VR’s potential in urological practice remains largely unexplored. Future studies are needed to validate VR’s efficacy, optimize its clinical applications, and establish standardized protocols for its integration into MSD management.
- 12 September 2025
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 14 (1)
Virtual reality in the management of male sexual dysfunction: an updated narrative review of the literature
Introduction: Virtual reality (VR) has emerged as a promising technology in medicine, offering innovative approaches for diagnostics, treatment, and patient education. However, its role in male sexual dysfunction (MSD) management remains underexplored, particularly among urologists. Objectives: To review the current evidence on the use of VR in the diagnosis and treatment of MSDs, assessing its feasibility, efficacy, and potential integration into clinical practice. Methods: A comprehensive bibliographic search for a narrative review was conducted in October 2024 using Google Scholar, PubMed, Scopus, and Web of Science to identify literature on VR applications in MSD management. The PICO framework of article selection was employed to include prospective and retrospective studies evaluating VR-based diagnostic and therapeutic interventions for MSD. Studies involving nonmale participants, nonsexual applications of VR, and technologies not classified as immersive VR (eg, televisions and laptops) were excluded. Results: In erectile dysfunction, VR-based audiovisual sexual stimulation (VR-AVSS) has demonstrated potential for assessing erectile function, providing an objective measure of arousal through RigiScan-based monitoring. Additionally, VR has been studied in psychosexual therapy, showing promise in managing performance anxiety and related psychological factors contributing to MSDs. In premature ejaculation, VR-based interventions may complement existing psychosexual and pharmacological treatments by facilitating behavioral training in immersive environments. While no clinical studies have directly examined VR applications in Peyronie’s disease, theoretical models suggest its utility in patient education and 3-dimensional curvature simulation, aiding treatment planning and adherence. Emerging applications of VR in forensic settings include the assessment of sexual preferences, aversion disorders, and deviant sexual behaviors, utilizing physiological and eye-tracking metrics to enhance diagnostic accuracy. Conclusion: While current research has predominantly focused on psychological interventions, VR’s potential in urological practice remains largely unexplored. Future studies are needed to validate VR’s efficacy, optimize its clinical applications, and establish standardized protocols for its integration into MSD management.
- 2 July 2025
- Published by Springer Nature in International Journal Of Impotence Research
- p. 1-8
Penile length preservation in penile prosthesis placement: tips & tricks
Penile Prosthesis (PP) is offered to patients with erectile dysfunction (ED) who prefer a definitive management, but subjective or objective penile length shortening after PP surgery is a concern. This review article aims to describe various preoperative, intraoperative and postoperative procedures and factors that may preserve or increase penile length during PP surgery. Preoperative strategies by the surgeon include vacuum erection devices (1 month), penile traction devices (2–4 months), and optimal surgical timing in priapism (early vs. delayed), and patient decisions include choosing a high-volume centre (>25 PP/year) and implant type (malleable vs. inflatable). The intraoperative manoeuvres included the subcoronal no-touch technique, cavernosal tissue-sparing dilatation, ventral phalloplasty, suspensory ligament release, suprapubic lipectomy, the sliding technique, the multiple-slit technique, and tunical expansion procedures. Simultaneous radical prostatectomy and PP surgery is gaining momentum to preserve the penile length in patients who have preexisting ED. Postoperative protocols included immediate postoperative inflation (60–80% inflated for 6 weeks), pump inflation protocol and the use of a vacuum device (without the ring, for 12 weeks). Using the above factors, the gain in penile length may range between 0.2 and 6.0 cm. The outcomes of these procedures are not universally reproducible at all centres.
- 2 July 2025
- Published by Springer Nature in International Journal Of Impotence Research
- p. 1-8
Penile length preservation in penile prosthesis placement: tips & tricks
Penile Prosthesis (PP) is offered to patients with erectile dysfunction (ED) who prefer a definitive management, but subjective or objective penile length shortening after PP surgery is a concern. This review article aims to describe various preoperative, intraoperative and postoperative procedures and factors that may preserve or increase penile length during PP surgery. Preoperative strategies by the surgeon include vacuum erection devices (1 month), penile traction devices (2–4 months), and optimal surgical timing in priapism (early vs. delayed), and patient decisions include choosing a high-volume centre (>25 PP/year) and implant type (malleable vs. inflatable). The intraoperative manoeuvres included the subcoronal no-touch technique, cavernosal tissue-sparing dilatation, ventral phalloplasty, suspensory ligament release, suprapubic lipectomy, the sliding technique, the multiple-slit technique, and tunical expansion procedures. Simultaneous radical prostatectomy and PP surgery is gaining momentum to preserve the penile length in patients who have preexisting ED. Postoperative protocols included immediate postoperative inflation (60–80% inflated for 6 weeks), pump inflation protocol and the use of a vacuum device (without the ring, for 12 weeks). Using the above factors, the gain in penile length may range between 0.2 and 6.0 cm. The outcomes of these procedures are not universally reproducible at all centres.
- Open Access
- 14 February 2025
- Published by Wolters Kluwer Health in Asian Journal of Andrology
- Vol. 28 (1) , 38-42
Excellent long-term device survival of inflatable penile prosthesis over 27 years
The study aimed to assess the long-term device survival of a 3-piece inflatable penile prosthesis (PP) in patients with erectile dysfunction (ED). This retrospective observational longitudinal study involved patients with drug-refractory ED who underwent primary 3-piece inflatable PP implantation at a single center from 1992 to 2019. The outcomes included complications of various inflatable PP models, and Kaplan–Meier analysis was used to estimate the probability of PP survival. Of the total 426 patients, 140 (32.9%) were implanted in the period of 1992–2000, 128 (30.0%) in the period of 2001–2008, and 158 (37.1%) in the period of 2009–2019. The PP used in the study included AMS 700 CX (62.0%, n = 264), AMS 700 CXR (7.7%, n = 33), AMS Ultrex Plus (10.3%, n = 44), and Alpha I (20.0%, n = 85). The overall complication rate was 28.2% (120/426), and the majority happened after 6 months. The causes of device removal included mechanical failure (11.0%, n = 47), infection (3.9%, n = 17), cylinder extrusion (6.3%, n = 27), and unspecified (0.2%, n = 1). Of the total mechanical failures ( n = 47), 18 (38.3%) occurred in the cylinders, 10 (21.3%) occurred in the pump, 7 (14.9%) occurred in the reservoir, 6 (12.8%) occurred in the connections, and 6 (12.8%) were nonspecific. Global average survival rates of the PP at 1 year, 5 years, 10 years, and 15 years were 96.2%, 86.7%, 77.5%, and 58.7%, respectively. The 3-piece inflatable PP has an excellent device survival rate at 5 years and 10 years.
- 14 February 2025
- Published by Wolters Kluwer Health in Asian Journal of Andrology
- Vol. 28 (1) , 38-42
Open AccessExcellent long-term device survival of inflatable penile prosthesis over 27 years
The study aimed to assess the long-term device survival of a 3-piece inflatable penile prosthesis (PP) in patients with erectile dysfunction (ED). This retrospective observational longitudinal study involved patients with drug-refractory ED who underwent primary 3-piece inflatable PP implantation at a single center from 1992 to 2019. The outcomes included complications of various inflatable PP models, and Kaplan–Meier analysis was used to estimate the probability of PP survival. Of the total 426 patients, 140 (32.9%) were implanted in the period of 1992–2000, 128 (30.0%) in the period of 2001–2008, and 158 (37.1%) in the period of 2009–2019. The PP used in the study included AMS 700 CX (62.0%, n = 264), AMS 700 CXR (7.7%, n = 33), AMS Ultrex Plus (10.3%, n = 44), and Alpha I (20.0%, n = 85). The overall complication rate was 28.2% (120/426), and the majority happened after 6 months. The causes of device removal included mechanical failure (11.0%, n = 47), infection (3.9%, n = 17), cylinder extrusion (6.3%, n = 27), and unspecified (0.2%, n = 1). Of the total mechanical failures ( n = 47), 18 (38.3%) occurred in the cylinders, 10 (21.3%) occurred in the pump, 7 (14.9%) occurred in the reservoir, 6 (12.8%) occurred in the connections, and 6 (12.8%) were nonspecific. Global average survival rates of the PP at 1 year, 5 years, 10 years, and 15 years were 96.2%, 86.7%, 77.5%, and 58.7%, respectively. The 3-piece inflatable PP has an excellent device survival rate at 5 years and 10 years.
- Open Access
- 29 January 2025
- Published by Wolters Kluwer Health in Journal of Association of Southern Urologists
- Vol. 2 (1) , 30-32
Mini Percutaneous Nephrolithotomy in a 7-month-old Infant Weighing 5.9 kg
A 7 month-1-day-old female child weighing 5.9 kg who presented with bilateral renal calculi and left ureteric calculus underwent bilateral mini (15 Fr) percutaneous nephrolithotomy (PCNL) and left ureterorenoscopy laser lithotripsy without any complications. This case report highlights the safety and efficacy of mini PCNL in the infant population using miniature endoscopes in dedicated pediatric urology centers of excellence.
- 29 January 2025
- Published by Wolters Kluwer Health in Journal of Association of Southern Urologists
- Vol. 2 (1) , 30-32
Open AccessMini Percutaneous Nephrolithotomy in a 7-month-old Infant Weighing 5.9 kg
A 7 month-1-day-old female child weighing 5.9 kg who presented with bilateral renal calculi and left ureteric calculus underwent bilateral mini (15 Fr) percutaneous nephrolithotomy (PCNL) and left ureterorenoscopy laser lithotripsy without any complications. This case report highlights the safety and efficacy of mini PCNL in the infant population using miniature endoscopes in dedicated pediatric urology centers of excellence.
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Indian Journal of Urology
- Vol. 41 (1) , 9-10
Andrology subspecialty: Training opportunities for Indian urologists
- 1 January 2025
- Published by Wolters Kluwer Health in Indian Journal of Urology
- Vol. 41 (1) , 9-10
Open AccessAndrology subspecialty: Training opportunities for Indian urologists
- 1 October 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (1) , 103-104
Response to comment on: penile prosthesis implantation is safe and effective in Peyronie’s disease patients with and without erectile dysfunction
- 1 October 2024
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (1) , 103-104
Response to comment on: penile prosthesis implantation is safe and effective in Peyronie’s disease patients with and without erectile dysfunction
- Open Access
- 25 July 2024
- Published by Wolters Kluwer Health in Journal of Association of Southern Urologists
- Vol. 1 (2) , 58-62
Correlation of Urodynamic Parameters to Long-term Outcomes Following Posterior Urethral Valve Fulguration
Introduction: A urodynamic study (UDS) is vital in the follow-up of a child with posterior urethral valve (PUV) to identify the type of bladder dysfunction and help develop a long-term management plan early. We have evaluated the urodynamic parameters after PUV fulguration and correlated them to the long-term outcomes. Materials and Methods: Forty children with PUV from August 1999 to June 2016 who fulfilled the inclusion criteria were included in this bidirectional study. The children diagnosed with PUV from August 1999 to September 2015 were included in the retrospective part of study and data collection was made by reviewing their hospital records. The children diagnosed after October 2015 till June 2016 onward were studied in a prospective methodology. Primary valve fulguration was done after adequate preoperative work up. On follow-up, weight and height estimation, bladder diary, urine routine and culture analysis, serum creatinine estimation, and ultrasound were done. Micturating cystourethrogram was done at either 3 or 6 monthly follow-up to see for any reflux. UDS was done during follow-up for those who had persistent hydroureteronephrosis or recurrent urinary tract infection (UTI). Independent t -test and Mann–Whitney U -test were used to calculate P value. After checking normality of the data, Pearson’s coefficient ( r ) was calculated. Results: On UDS, 95% of children had normal bladder sensation. Twenty-seven (67.5%) had normal bladder compliance (BC). Thirteen (32.5%) had detrusor overactivity (DO), which was more common in the 1–5 years’ age group. Five of nine children (55%) who had recurrent UTI had poor BC. Cystometric capacity showed significant association with anteroposterior diameter (APD) of the right renal pelvis ( P = 0.013), APD of the left renal pelvis ( P = 0.027), and APD of the right ureter ( P = 0.041). Detrusor pressure at peak flow showed a significant association with APD of the left ureter ( P = 0.05). Peak flow showed a significant association with APD of the right ureter ( P = 0.009). Eight-year survival rate was 48% for glomerular filtration rate (GFR) 30 as an event. Log-rank showed statistically significant ( P = 0.038) survival difference in GFR between children with normal and poor BC. Conclusion: UDS should be done during follow-up of PUV children when indicated to delay or prevent the onset of end-stage renal disease.
- 25 July 2024
- Published by Wolters Kluwer Health in Journal of Association of Southern Urologists
- Vol. 1 (2) , 58-62
Open AccessCorrelation of Urodynamic Parameters to Long-term Outcomes Following Posterior Urethral Valve Fulguration
Introduction: A urodynamic study (UDS) is vital in the follow-up of a child with posterior urethral valve (PUV) to identify the type of bladder dysfunction and help develop a long-term management plan early. We have evaluated the urodynamic parameters after PUV fulguration and correlated them to the long-term outcomes. Materials and Methods: Forty children with PUV from August 1999 to June 2016 who fulfilled the inclusion criteria were included in this bidirectional study. The children diagnosed with PUV from August 1999 to September 2015 were included in the retrospective part of study and data collection was made by reviewing their hospital records. The children diagnosed after October 2015 till June 2016 onward were studied in a prospective methodology. Primary valve fulguration was done after adequate preoperative work up. On follow-up, weight and height estimation, bladder diary, urine routine and culture analysis, serum creatinine estimation, and ultrasound were done. Micturating cystourethrogram was done at either 3 or 6 monthly follow-up to see for any reflux. UDS was done during follow-up for those who had persistent hydroureteronephrosis or recurrent urinary tract infection (UTI). Independent t -test and Mann–Whitney U -test were used to calculate P value. After checking normality of the data, Pearson’s coefficient ( r ) was calculated. Results: On UDS, 95% of children had normal bladder sensation. Twenty-seven (67.5%) had normal bladder compliance (BC). Thirteen (32.5%) had detrusor overactivity (DO), which was more common in the 1–5 years’ age group. Five of nine children (55%) who had recurrent UTI had poor BC. Cystometric capacity showed significant association with anteroposterior diameter (APD) of the right renal pelvis ( P = 0.013), APD of the left renal pelvis ( P = 0.027), and APD of the right ureter ( P = 0.041). Detrusor pressure at peak flow showed a significant association with APD of the left ureter ( P = 0.05). Peak flow showed a significant association with APD of the right ureter ( P = 0.009). Eight-year survival rate was 48% for glomerular filtration rate (GFR) 30 as an event. Log-rank showed statistically significant ( P = 0.038) survival difference in GFR between children with normal and poor BC. Conclusion: UDS should be done during follow-up of PUV children when indicated to delay or prevent the onset of end-stage renal disease.